München, Germany, April 20, 2013 --(PR.com
)-- On 4 June, 2013 business developers and venture capitalists looking for cutting-edge life-science inventions will gather in Munich for the 6th annual BioVaria conference. This year, 13 technology transfer organizations from all over Europe will present the most promising projects from their partner institutes: diagnostic and therapeutic projects as well as platform technologies. Following peer review, BioVaria's advisory board has accepted only those technologies that meet the requirements of industry and investors.
Ascenion's partner institutes will present novel approaches targeting significant medical needs in the fields of Alzheimer's disease, tuberculosis, liver regeneration and depression.
For further information and a full preview of technologies that have been accepted for BioVaria 2013 visit www.biovaria.org.
The proven BioVaria Format, with its short presentations and poster exhibition, gives industry representatives a good overview and allows plenty of opportunity for individual discussions with scientists and their technology transfer representatives.
This year, there will also be a Spin-off Panel for European start-ups who will present their business to a jury of industry representatives and investors in an interactive format. The Panel will be chaired by Jorn Fingerhuth, Partner at Pinsent Masons.
BioVaria brings together Europe's top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.
Key features of BioVaria:
- Comprehensive overview of life-science technologies and spin-offs originating from European academic research
- Focus on patent-protected, commercially attractive opportunities covering research tools, diagnostics and therapeutics in different disease areas.
- Interactive, efficient one-day format
- Ample space to discuss scientific details face-to-face with the inventors.
Bavarian State Ministry for Economic Affairs, Infrastructure, Transport and Technology
Sponsors gained so far:
BioM, Bayer HealthCare, Boehringer Ingelheim, MSD, Novo Nordisk, HERTIN, Sanofi, Vossius & Partner, Pinsent Masons, Bayern Kapital
Partners gained so far:
Ascenion, Austria Wirtschaftsservice Gesellschaft, Bayerische Patentallianz, BTO Bergen Teknologioverføring, EMBLEM Technology Transfer, FIST, Inven2, ipal, Lead Discovery Center, Max-Planck-Innovation, MRCT - Medical Research Council Technology, National Genome Research Network, PROvendis
Communication supporters gained so far:
ASTP, BioDeutschland, GoingPublic, iptechex, KONOCOM, transkript
About Ascenion GmbH
Ascenion GmbH is an IP asset management company with particular expertise in the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property, and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion currently markets around 750 technologies on behalf of its institutions.
Further information at www.ascenion.de
Dr. Susanne Letzelter, Corporate Development & Communication
T: +49 (0)89 318814-16, E: email@example.com
Ascenion GmbH, Herzogstraße 64, 80803 München